This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dexamethasone and Block Duration in Upper Extremity

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2014 by University of Chicago.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
University of Chicago Identifier:
First received: December 20, 2012
Last updated: March 27, 2014
Last verified: March 2014
Effect of dexamethasone on prolonging upper extremity block is well known. But it not known if the effect comes from its local effect on the nerves or from its general analgesic effect. In this study we will compare the systemic effect to its local effect to find out if there is a difference or not.

Condition Intervention Phase
Duration of Pain Relief Drug: Dexamthsone Drug: Bupivacaine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study of the Effect of Dexamethasone on Duration of Upper Extremity Blocks With Bupivacaine

Resource links provided by NLM:

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • analgesia duration [ Time Frame: 72 hrs ]

Estimated Enrollment: 60
Study Start Date: January 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Bupivacaine
Drug: Bupivacaine
Experimental: Bupivacaine with Dexamethasone
Dexamethasone will be mixed with bupivacaine
Drug: Dexamthsone Drug: Bupivacaine
Active Comparator: Intravenous Dexamethasone
Dexamethasone will be given intravenously
Drug: Dexamthsone Drug: Bupivacaine


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18-75, no contraindication to regional anesthesia,

Exclusion Criteria:

  • opioid user, chronic pain conditions, peripheral neuropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01756573

Contact: Tariq Malik

United States, Illinois
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
Principal Investigator: Tariq Malik, MD         
Sponsors and Collaborators
University of Chicago
  More Information

Responsible Party: University of Chicago Identifier: NCT01756573     History of Changes
Other Study ID Numbers: IRB12-2192
Study First Received: December 20, 2012
Last Updated: March 27, 2014

Keywords provided by University of Chicago:
block duration

Additional relevant MeSH terms:
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anesthetics, Local
Central Nervous System Depressants
Sensory System Agents processed this record on September 21, 2017